man undergoing radiotherapy

Image credit: Netherlands Cancer Institute

News • Personalizing treatment

AI can help improve precision radiotherapy

The Netherlands Cancer Institute, University of Amsterdam (UvA), and Elekta will collaborate on the development of new AI strategies for the further improvement of precision radiotherapy.

This concerns the personalization of treatment by improving the quality of imaging used during treatment, predicting and accounting for changes in the patient’s anatomy over time, and automatically adapting radiation delivery each time a patient is treated.

The collaborating parties have recently been awarded a grant of the Rijksdienst voor Ondernemend Nederland (RVO), making the Partnership for Online Personalized AI-driven Adaptive RT (POP-AART) lab a reality. The lab, part of the Innovation Center for Artificial Intelligence (ICAI), aims to use state-of-the-art AI methods to optimize online adaptive radiotherapy. The goal of adaptive radiotherapy is to account for changes that can occur in patients over the course of treatment and to ‘adapt’ the original prescription for every day of treatment to ensure the right dose is delivered at the right time to the right location, with minimal damage to healthy tissue. This a great challenge that should be a part of every treatment session, because the patient and the tumor are continuously in motion and change shape over time. In the past, this has been impossible to achieve due to computational and workflow complexities, but AI has the potential to make that achievable in the near future.

We believe AI has a critical role to play in assisting clinicians to provide increasingly personalized and complex cancer treatment to patients

Maurits Wolleswinkel

Jan-Jakob Sonke, group leader adaptive radiotherapy, professor by special appointment at the UvA, and one of the two lab directors, greatly looks forward to the start of the lab. 'Not only is it our ambition to create incredibly innovative AI algorithms – we also want to make sure that they can be applied to clinical practice so patients can receive even better treatment'. Efstratios Gavves, associate professor on computer vision and deep learning at the UvA, and director of the lab: 'The time is ripe to combine the power of Artificial Intelligence and big data with the cutting-edge expertise of the University of Amsterdam and the Netherlands Cancer Institute, for an application with tremendous impact: battling cancer.'

The lab will pioneer the use of novel deep learning approaches to address challenges in modern radiation oncology including personalization, speed, and precision. Multiple work streams will run in parallel over the course of the partnership, and each will address various key elements in the radiotherapy process including the quality of daily treatment images, and strategies to detect and adapt for changes in a patient’s anatomy and methods to continually personalize the treatment plan for patients. Maurits Wolleswinkel, President Linac Solutions & Chief Product Officer at Elekta, says 'We believe AI has a critical role to play in assisting clinicians to provide increasingly personalized and complex cancer treatment to patients. Elekta’s participation in POP-AART underlines our commitment to precision radiation medicine.'


Source: University of Amsterdam

20.07.2021

Read all latest stories

Related articles

Photo

Article • The future has begun

Cancer care 2035: multi-disciplinarity is key

An enthralling insight into the care that could be offered to cancer patients of the future was presented by cancer imaging expert Professor Regina Beets-Tan during her a keynote presentation at the…

Photo

News • AI approach to colorectal tumors

Deep learning identifies molecular patterns of cancer

A new AI platform can analyze genomic data extremely quickly, picking out key patterns to classify different types of colorectal tumors and improve the drug discovery process.

Photo

News • Machine learning vs. NSCLC

AI to improve post-treatment surveillance of lung cancer patients

Artificial intelligence (AI) could help guide the post-treatment surveillance of non-small cell lung cancer (NSCLC) patients and improve outcomes as a result, according to a new study.

Related products

Canon – Advanced intelligent Clear-IQ Engine for MR

Artificial Intelligence

Canon – Advanced intelligent Clear-IQ Engine for MR

Canon Medical Systems Europe B.V.
Canon - CT Image Reconstruction

Artificial Intelligence

Canon - CT Image Reconstruction

Canon Medical Systems Europe B.V.
Canon - HIT Automation Platform

Artificial Intelligence

Canon - HIT Automation Platform

Canon Medical Systems Europe B.V.
Canon - Vantage Elan NX Edition

1.5 Tesla

Canon - Vantage Elan NX Edition

Canon Medical Systems Europe B.V.
Fujifilm · REiLI

Artificial Intelligence

Fujifilm · REiLI

FUJIFILM Europe GmbH
Agfa HealthCare – Rubee for AI

Artificial Intelligence

Agfa HealthCare – Rubee for AI

Agfa HealthCare
Subscribe to Newsletter